TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23576020

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with cisplatin (40 mg/m2 weekly during RT, followed by cisplatin (80 mg/m2) and fluorouracil (800 mg/m2) daily for 5 days every 4 weeks for 3 cycles)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 316
Study: 21851917

Group type: EXPERIMENTAL
Intervention: Reinforcement intervention (opportunities to win $1 to $100 prizes for losing weight and completing weight-loss activities)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-reinforcement condition (Lifestyle, Exercise, Attitudes, Relationships, Nutrition manual with supportive counseling)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Reinforcement intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-reinforcement condition
Number of subjects: 56
Study: 20533221

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient‐fortified salt
Number of subjects: 402

Group type: COMPARATOR
Intervention: Iodized salt
Number of subjects: 402
Study: 17245777

Group type: EXPERIMENTAL
Intervention: Group pelvic floor muscle training (PFMT) under intensive supervision (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Individual home therapy (Group A)
Number of subjects: 30
Study: 15090951

Group type: EXPERIMENTAL
Intervention: Alcoholic povidone-iodine solution protocol
Number of subjects: 223

Group type: COMPARATOR
Intervention: Aqueous 10% povidone-iodine solution protocol
Number of subjects: 223
Study: 11213982

Group type: EXPERIMENTAL
Intervention: Diclofenac 150 mg orally (50 mg rapid-release and 100 mg prolonged-release)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg orally (prolonged-release) and 50 mg intramuscularly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diclofenac (equal doses)
Number of subjects: 30
Study: 11783221

Group type: EXPERIMENTAL
Intervention: Huodan Tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 0
Study: 7991079

Group type: EXPERIMENTAL
Intervention: Indirect memory performance for abstract shapes (copying speed)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two-choice recognition of shapes
Number of subjects: 12
Study: 2663152

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trazodone or another antidepressant
Number of subjects: 42
Study: 4818344

Group type: EXPERIMENTAL
Intervention: Heparin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 31771410

Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (in-person care)
Number of subjects: 71
Study: 31517677

Group type: EXPERIMENTAL
Intervention: Surgical Pleth Index (SPI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pupillary Pain Index (PPI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nociception Level (NoL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Clinical judgment (control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PPI
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NoL
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SPI
Number of subjects: 48
Study: 29187423

Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) follow-up care
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard outpatient care (SOC)
Number of subjects: 182
Study: 28333187

Group type: EXPERIMENTAL
Intervention: Eldelumab 20 mg/kg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Eldelumab 10 mg/kg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Eldelumab (both doses)
Number of subjects: 121
Study: 26465664

Group type: EXPERIMENTAL
Intervention: Vocal warm-up
Number of subjects: 31

Group type: COMPARATOR
Intervention: Breathing training
Number of subjects: 31
Study: 23621698

Group type: EXPERIMENTAL
Intervention: Continuous therapy with infliximab 5 mg kg(‐1) every 8 weeks
Number of subjects: 441

Group type: COMPARATOR
Intervention: Intermittent therapy (no infliximab until > 50% loss of PASI improvement)
Number of subjects: 441
Study: 21252632

Group type: EXPERIMENTAL
Intervention: Weekly SMS reminders
Number of subjects: 431

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 431
Study: 18450869

Group type: EXPERIMENTAL
Intervention: Newborn Individualized Developmental Care and Assessment Program care
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 36
Study: 16531506

Group type: EXPERIMENTAL
Intervention: Lower birth weight (LBW) group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Higher birth weight (HBW) group
Number of subjects: 29
Study: 15055982

Group type: EXPERIMENTAL
Intervention: 19% sodium percarbonate gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 50
Study: 11899648

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 114
Study: 9197167

Group type: EXPERIMENTAL
Intervention: Metronidazole 800 mg tid for 10 days combined with needle aspiration (group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Metronidazole therapy alone (group B)
Number of subjects: 29
Study: 8298940

Group type: COMPARATOR
Intervention: Control group (Haemoccult screening)
Number of subjects: 405
Study: 3812347

Group type: EXPERIMENTAL
Intervention: Iron-fortified milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonfortified milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncompliant fortified group
Number of subjects: 0
Study: 31912170

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery (RS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic surgery (LS)
Number of subjects: 0
Study: 28506442

Group type: EXPERIMENTAL
Intervention: Musical primes during morphosyntactic training exercises (8 sessions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Neutral baseline primes (environmental sounds) during morphosyntactic training exercises (8 sessions)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Musical primes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Attention tasks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Memory tasks
Number of subjects: 10
Study: 27043120

Group type: EXPERIMENTAL
Intervention: CurQfen (curcumagalactomannoside [CGM]) 500 mg twice daily for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard curcumin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24184388

Group type: EXPERIMENTAL
Intervention: Morphine (30 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21819446

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) - 5 × 1 min of unilateral isometric squat exercise on a synchronous vibrating platform [30 Hz, 4 mm peak‐to‐peak amplitude]
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition (CON) - same exercise without WBV
Number of subjects: 14
Study: 21946190

Group type: EXPERIMENTAL
Intervention: Tdap vaccine (5-pertussis-component)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No vaccine (control group)
Number of subjects: 0
Study: 18289869

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional immunosuppressive therapy (CIST)
Number of subjects: 22
Study: 16537263

Group type: EXPERIMENTAL
Intervention: Computer‐Assisted Memory Training Group (CAMG)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Therapist‐administered Memory Training Group (TAMG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 37
Study: 12783233

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal unstimulated perfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 0
Study: 10735888

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus CMF (cyclophosphamide, methotrexate, fluorouracil)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: CMF plus tamoxifen
Number of subjects: 608
Study: 8958002

Group type: EXPERIMENTAL
Intervention: Malted-oat porridge with 107 mumol phytate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control porridge with 432 mumol phytate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Malted-oat porridge with 107 mumol phytate (Expt 2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control porridge with 437 mumol phytate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Malted porridge with 198 mumol phytate (Expt 3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control porridge with 599 mumol phytate
Number of subjects: 10
Study: 1488468

Group type: EXPERIMENTAL
Intervention: Caffeine (7 mg/kg)
Number of subjects: 14
Study: 2857265

Group type: EXPERIMENTAL
Intervention: Experimental diet high in polyunsaturated fat and low in saturated fat with daily supplement of 1.8 g eicosapentaenoic acid
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control diet with lower polyunsaturated to saturated fat ratio and placebo supplement
Number of subjects: 37
Study: 30854818

Group type: EXPERIMENTAL
Intervention: XPF 3 mL of 3% NaOCl for 1 min (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PUI of 3 mL of 3% NaOCl for 1 min (group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 mL of 3% NaOCl for 1 min by using a syringe and a 30 G side‐vented needle (group E)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: XPF 3 mL of 3% NaOCl for 1 min, followed by 4 mL of 17% EDTA for 1 min (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PUI of 3 mL of 3% NaOCl for 1 min, followed by 4 mL of 17% EDTA for 1 min (group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 mL of 3% NaOCl for 1 min by using a syringe and a 30 G side‐vented needle, followed by 4 mL of 17% EDTA for 1 min (group F)
Number of subjects: 60
Study: 29436706

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 13
Study: 26785826

Group type: EXPERIMENTAL
Intervention: Deferiprone (dosage not specified)
Number of subjects: 0
Study: 25414061

Group type: EXPERIMENTAL
Intervention: Transvaginal hybrid NOTES
Number of subjects: 58

Group type: COMPARATOR
Intervention: Laparoscopic‐assisted sigmoid resection
Number of subjects: 58
Study: 23017985

Group type: EXPERIMENTAL
Intervention: Aquatic exercise program (3 times per week for 8 weeks, 60 minutes per session)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (following oncologist's recommendations)
Number of subjects: 68
Study: 20447123

Group type: EXPERIMENTAL
Intervention: Medmont automated perimeter (MAP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Humphrey field analyser (HFA)
Number of subjects: 63
Study: 18725429

Group type: EXPERIMENTAL
Intervention: Anger expression condition (telling stories about people depicted in pictures)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Anger inhibition condition (describing objects appearing in pictures)
Number of subjects: 84
Study: 16173015

Group type: EXPERIMENTAL
Intervention: GigHAART therapy after an 8-week treatment interruption (TI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple drug salvage regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined factor of PI concentration and genotypic score (GIQ)
Number of subjects: 0
Study: 12887479

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once-daily
Number of subjects: 955

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 955
Study: 10482340

Group type: EXPERIMENTAL
Intervention: Noradrenergic antidepressant desipramine (n = 38)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Selective serotonin re‐uptake inhibitor (paroxetine or sertraline) (n = 38)
Number of subjects: 76
Study: 8529508

Group type: EXPERIMENTAL
Intervention: Intensive therapy to achieve a haemoglobin A1c level of 7.1%
Number of subjects: 4209

Group type: EXPERIMENTAL
Intervention: Improved glucose control
Number of subjects: 4209

Group type: EXPERIMENTAL
Intervention: Specific therapies (sulphonylurea, metformin, insulin)
Number of subjects: 4209

Group type: COMPARATOR
Intervention: Standard control group
Number of subjects: 4209
Study: 2188871

Group type: EXPERIMENTAL
Intervention: Oral S-adenosylmethionine (1600 mg/day)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 340330

Group type: EXPERIMENTAL
Intervention: Cimetidine (0.8 to 2.0 g per day)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 348
Study: 30666969

Group type: EXPERIMENTAL
Intervention: Synbiotic therapy for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison between synbiotic and control groups
Number of subjects: 40
Study: 28058763

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Serious hypoglycaemia (combined treatment groups)
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Baseline HbA1c levels
Number of subjects: 5380
Study: 25668008

Group type: EXPERIMENTAL
Intervention: Text-message reminder 48 hours before appointment
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Normal invitation only
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Text-message reminder for those with mobile numbers recorded
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Normal invitation for those with mobile numbers recorded
Number of subjects: 2240
Study: 23391635

Group type: EXPERIMENTAL
Intervention: S‐Monovette® serum tube collected with manual aspiration (SD‐A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard vacuum tube (BD‐V)
Number of subjects: 52

Group type: COMPARATOR
Intervention: S‐Monovette® serum tube collected by vacuum (SD‐V)
Number of subjects: 52
Study: 21507689

Group type: EXPERIMENTAL
Intervention: Artificial saliva
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 3% citric acid
Number of subjects: 54

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 54
Study: 19623191

Group type: EXPERIMENTAL
Intervention: 3-year school-based intervention targeting nutrition and physical activity behaviors
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Structured observations of physical education classes, total school food environments, classroom-based educational modules, and communications and promotional campaigns
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interviews and focus groups
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Process evaluation methods and procedures
Number of subjects: 21
Study: 16454016

Group type: EXPERIMENTAL
Intervention: Chemical tooth whitening system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light-activated tooth whitening system
Number of subjects: 0
Study: 15293484

Group type: EXPERIMENTAL
Intervention: Combined training (CT, N=39)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Home training (HT, N=38)
Number of subjects: 77
Study: 10855905

Group type: EXPERIMENTAL
Intervention: Categorical scale for muscle tone assessment (spastic/normal/flaccid)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (score 0 to 100) for muscle tone assessment
Number of subjects: 39
Study: 9034227

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 241
Study: 8050027

Group type: EXPERIMENTAL
Intervention: Water jet guided Nd:YAG laser
Number of subjects: 89

Group type: COMPARATOR
Intervention: Non-contact Nd:YAG laser
Number of subjects: 89
Study: 3524607

Group type: EXPERIMENTAL
Intervention: Polycarbonate membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cuprophane membranes
Number of subjects: 0
Study: 31262193

Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No taping (NT)
Number of subjects: 9
Study: 29444968

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) with diaphragmatic breathing
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control focused‐attention activity with extremity movements
Number of subjects: 66
Study: 27590170

Group type: EXPERIMENTAL
Intervention: Behavioral intervention involving home visits, standardized advice, a booklet, daily telephone calls for reinforcement, and a reinforcement visit on day 3.
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (as described above)
Number of subjects: 552
Study: 25048810

Group type: EXPERIMENTAL
Intervention: Health guidance by occupational health staff with visceral fat measurements and a weight loss support web system
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Health guidance by occupational health staff with a weight loss support web system
Number of subjects: 181

Group type: COMPARATOR
Intervention: Without health guidance (control)
Number of subjects: 181
Study: 22391168

Group type: EXPERIMENTAL
Intervention: F regimen (fludarabine 30 mg/(m(2)·d) intravenously for 3 d, every 28 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: FC regimen (fludarabine 25 mg/(m(2)·d) plus cyclophosphamide 250 mg/(m(2)·d) intravenously for 3 d, every 28 days)
Number of subjects: 40
Study: 20418244

Group type: EXPERIMENTAL
Intervention: Thalidomide-interferon
Number of subjects: 128

Group type: COMPARATOR
Intervention: Interferon
Number of subjects: 128
Study: 18424354

Group type: EXPERIMENTAL
Intervention: He‐Ne laser therapy (wavelength 632.8 nm, administered locally at 3.0 J/cm2, once or twice weekly)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: He‐Ne laser therapy
Number of subjects: 40
Study: 15972594

Group type: EXPERIMENTAL
Intervention: Active occlusal interference
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dummy interference
Number of subjects: 11
Study: 12794182

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO trial)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 8
Study: 10570726

Group type: COMPARATOR
Intervention: Migraine patients
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Chronic tension-type headache patients
Number of subjects: 81

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 81
Study: 8975448

Group type: EXPERIMENTAL
Intervention: Continuous cold pressure therapy
Number of subjects: 24
Study: 1898630

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 750 mg, orally twice daily for 14 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (nonparticipants)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (overall)
Number of subjects: 28
Study: 6307500

Group type: EXPERIMENTAL
Intervention: 6-hour IV infusion of highly purified human lymphoblastoid interferon (HLBI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IM injection of highly purified human lymphoblastoid interferon (HLBI)
Number of subjects: 40
Study: 31672261

Group type: EXPERIMENTAL
Intervention: Kangaroo care applied once a day for three weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (15-20 min visit once a day for five days a week for three weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kangaroo care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 30648303

Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT) for 12 months with usual REMS treatments (n=10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual REMS treatments alone (n=11)
Number of subjects: 21
Study: 28763358

Group type: EXPERIMENTAL
Intervention: Esmolol (IV bolus dose of 1 mg/kg followed by infusion of 10 μg·kg·minute over 15 minutes)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Remifentanil (target-controlled infusion of 4 ng/mL over 15 minutes)
Number of subjects: 14
Study: 25349059

Group type: EXPERIMENTAL
Intervention: Combination treatment with mechanical support and targeted intra-arterial infusion of PBSCs
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mechanical support treatment (control group)
Number of subjects: 55
Study: 23281692

Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NB-UVB
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 21073981

Group type: EXPERIMENTAL
Intervention: Optimized rapeseed oil and margarine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard rapeseed oil and margarine
Number of subjects: 59
Study: 19137426

Group type: EXPERIMENTAL
Intervention: 1 year endocrine treatment alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine alone or no treatment
Number of subjects: 0
Study: 15832952

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2000 microg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 2000 microg/day
Number of subjects: 15
Study: 15321057

Group type: EXPERIMENTAL
Intervention: 20 Gy dose delivered at 1 mm beyond mean reference lumen
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 20 Gy dose delivered at 1 mm beyond mean reference external elastic membrane
Number of subjects: 47
Study: 10584776

Group type: EXPERIMENTAL
Intervention: Bright light therapy at 10,000 lux for 30 minutes daily for 10 to 14 days
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Morning light treatment
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Evening light treatment
Number of subjects: 83
Study: 8683171

Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass circuits (Duraflow-II) with 200 IU/kg heparin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-coated cardiopulmonary bypass circuits with 350 IU/kg heparin
Number of subjects: 59